Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Målt kryospray til behandling af patienter med kronisk obstruktiv lungesygdom med kronisk bronkitis

25. september 2026 opdateret af: CSA Medical, Inc.

Karakterisering af virkningsmekanismen af ​​målt kryospray til behandling af patienter med kronisk obstruktiv lungesygdom med kronisk bronkitis

To evaluate the relationship between airway structure and function in patients with chronic bronchitis treated with metered cryospray (MCS).

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

To identify the molecular and cellular targets of MCS treatment and determine the mechanistic relationship to airways remodelling in patients with chronic bronchitis. Phenotype, characterise and correlate clinical, physiological, histological and molecular parameters in patients with chronic bronchitis.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

32

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • London, Det Forenede Kongerige, SW3 6NP
        • The Royal Brompton Hospital
      • Groningen, Holland
        • University Medical Center Groningen

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år til 79 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Each Subject must meet the following criteria to be enrolled in the study:

  1. Males and females ≥40 to <80 years of age.
  2. Subject is able to read, understand, and sign a written Informed Consent in order to participate in the study.
  3. Subject has a diagnosis of CB and COPD and has been symptomatic for a minimum of two years. (Chronic Bronchitis is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded).
  4. Subject is classified as having moderate or severe (GOLD stage 2-3) airflow obstruction defined by a post-bronchodilator of =>30% FEV1 to <80% predicted with a baseline FEV1/FVC of <0.70.
  5. Subject has a COPD assessment tool (CAT) score of ≥10.
  6. Subject is being treated according to current medically accepted treatment guidelines without successful resolution of chronic bronchitis and agrees to continue maintenance pulmonary/COPD medications (as defined per GOLD Standard for medications) for the duration of the study (subject must be on a regime of pulmonary medications for a minimum of 2 weeks prior to enrolment into the study).
  7. Smoking history of at least 10 pack years.
  8. Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study.
  9. Subject is able to adhere to and undergo 4 bronchoscopic procedures (5 for control subjects accepting cross over option), in the opinion of the investigator or per hospital guidelines.
  10. For women of childbearing potential: non-pregnant, non-lactating, and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  1. Subject has had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 6 weeks of initially planned study bronchoscopy.
  2. Diagnosis of asthma with an onset before 30 years of age.
  3. Subject has Alpha-1 antitrypsin deficiency.
  4. Subject has other origins of respiratory disease aside from chronic bronchitis and COPD.
  5. Subject is using e-cigarettes, vaping or taking any oral or inhaled substances not prescribed by a physician.
  6. Subject has untreatable or life-threatening arrhythmias, or history of inability to adequately oxygenate during a bronchoscopy, or has acute respiratory failure with hypercapnia.
  7. Subject has bullous emphysema characterized as large bullae >30 millimetres on HRCT; or subject has stenosis in the tracheobronchial system, tracheobronchomegaly, trachea-bronchomalacia, amyloidosis or cystic fibrosis.
  8. Subject has clinically significant bronchiectasis
  9. Subject has had a transplant procedure (any).
  10. Subject has a known mucosal tear, has undergone prior lung surgery such as pneumonectomy, lobectomy, bullectomy, or lung volume reduction surgery, bronchial thermoplasty, rheoplasty or cryotherapy.
  11. Subject has had a prior lung device procedure, including emphysema stent(s) implanted, lung coils, valves, lung denervation or other devices for emphysema.
  12. Subject is unable to temporarily discontinue use of anticoagulant therapy: warfarin, Coumadin, LMWH, heparin, clopidrogel (or equal).
  13. Subject has a serious medical condition, such as: uncontrolled coagulopathy or bleeding disorder, congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, uncontrolled hypertension, autoimmune disease or uncontrolled gastric reflux.
  14. Subject has or is receiving chemotherapy or active radiation therapy within the past 6 months or is expected to receive chemotherapy during participation in this study.
  15. Subject is or has been in another clinical investigational study within 6 weeks of enrolment.
  16. Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Treatment

MCS

Bronchial metered cryospray using RejuvenAir® System.

Sham-komparator: Sham Control

Sham

Sham control procedure

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Goblet cell density
Tidsramme: 6-months post treatment

Difference in change relative to baseline in goblet cell density per mm of basement membrane in endobronchial cryobiopsies at 6-months between treatment and sham-control groups

6-months post treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Histopathological examination of endobronchial cryobiopsies to determine Inflammatory cells and subtype density per mm of basement membrane
Tidsramme: 6-months post treatment

Proportion of inflammatory cells per mm of basement membrane for Neutrophil and Lymphocyte sequencing (RNA-seq)

6-months post treatment
Histopathological examination of endobronchial cryobiopsies to determine epithelial cell density and area (including respiratory epithelial, goblet and basal cells) per mm of basement membrane
Tidsramme: 6-months post treatment

Proportion of epithelial cells per mm of basement membrane for Ciliary and Goblet cells

6-months post treatment
Transcriptomics: Epithelial gene expression as measured by global gene expression sequencing (RNA-seq)
Tidsramme: 6-months post treatment

Transcriptomics: Epithelial gene expression as measured by global gene expression sequencing (RNA-seq)

6-months post treatment
Pulmonary function tests including spirometry, body plethysmography and transfer factors KCO and TLCO
Tidsramme: 6-months post treatment

Pulmonary function tests including spirometry, body plethysmography and transfer factors KCO and TLCO

6-months post treatment
Patient reported outcome measures including SGRQ, mMRC, CAT and Cough Questionnaires
Tidsramme: 6-months post treatment

Patient reported outcome measures including SGRQ, mMRC, CAT and Cough Questionnaires

6-months post treatment
Health care utilisation assessments including number of respiratory exacerbations, emergency room visits, hospital and intensive care unit admissions related to respiratory adverse events
Tidsramme: 6-months post treatment

Health care utilisation assessments including number of respiratory exacerbations, emergency room visits, hospital and intensive care unit admissions related to respiratory adverse events

6-months post treatment
The 6-minute walk tests
Tidsramme: 6-months post treatment

The 6-minute walk tests

6-months post treatment

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Microvesicle quantification
Tidsramme: 6-months post treatment

Microvesicle quantification

6-months post treatment
Lobar volumes and gas trapping as determined by quantitative CT and parametric response mapping
Tidsramme: 6-months post treatment

Lobar volumes and gas trapping as determined by quantitative CT and parametric response mapping

6-months post treatment
Small airways function as assessed by Impulse Oscillometry (IOS)
Tidsramme: 6-months post treatment

Small airways function as assessed by Impulse Oscillometry (IOS)

6-months post treatment
Composition of epithelial ultrastructure as assessed by transmission electron microscopy
Tidsramme: 6-months post treatment

Composition of epithelial ultrastructure as assessed by transmission electron microscopy

6-months post treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Pallav Shah, MD, The Royal Brompton Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. februar 2020

Primær færdiggørelse (Faktiske)

11. juli 2022

Studieafslutning (Faktiske)

12. december 2022

Datoer for studieregistrering

Først indsendt

26. marts 2019

Først indsendt, der opfyldte QC-kriterier

26. marts 2019

Først opslået (Faktiske)

27. marts 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner